Omada Health, Inc. (OMDA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Omada Health, a digital health provider specializing in chronic disease management, presented at the Morgan Stanley Global Healthcare Conference, highlighting strong Q2 revenue of $61 million, up 49% year-over-year, and a membership of 752,000. The company's growth is propelled by its multi-condition offerings, a successful GLP-1 Care Track supporting over 100,000 members with significantly reduced weight regain post-discontinuation, and the strategic integration of AI via Omada Spark to enhance member engagement and care team efficiency. Omada projects long-term gross margins exceeding 70% and EBITDA over 20%, leveraging its proprietary care delivery platform and ability to bill into medical spend, positioning it as a key solution amid rising healthcare costs and the increasing focus on metabolic disease.

Analysis

Omada Health (OMDA) is demonstrating strong post-IPO momentum, underscored by its Q2 results featuring $61 million in revenue, a 49% year-over-year growth rate, and a member base of 752,000. The company is strategically capitalizing on the burgeoning GLP-1 market through its GLP-1 Care Track, which now supports over 100,000 members. A pivotal new study showing members regain only 0.8% of weight 12 months after discontinuing GLP-1s, compared to an expected 11%, provides a powerful value proposition for payers concerned with the high cost and long-term efficacy of these drugs. Management views this as a 'gateway' to broader sales, as it addresses payer concerns about waste and opens doors to conversations about Omada's full suite of metabolic solutions. This is complemented by a successful multi-product strategy, with over 31% of its 2,000+ customers now using Omada for multiple conditions (e.g., diabetes, hypertension, MSK), which drives higher average revenue per user (ARPU) and operational leverage. Furthermore, the integration of AI through its 'Omada Spark' platform is already showing promise, with pilot data indicating a 20% efficiency gain for care teams. This technology is a key lever for achieving the company's long-term financial targets, which include a 70%+ gross margin and a 20%+ EBITDA margin, supported by a scalable, proprietary care delivery platform and a business model that bills directly into medical spend.

Key Decisions for Investors

• Investors should view Omada's GLP-1 Care Track not as a competitor but as a critical enabler for the broader GLP-1 drug market, which positions the company to capture value from payers seeking to maximize the ROI of their high-cost pharmaceutical spend.
• Monitor the rate of multi-condition adoption among Omada's customer base, as success in cross-selling is a primary driver for both revenue acceleration and the operating leverage needed to reach the company's stated 20%+ long-term EBITDA margin target.
• While the company's guidance of 40% revenue growth is strong, the key long-term catalyst is the successful implementation of AI-driven efficiencies to expand gross margins beyond the 70% target, which would significantly accelerate the path to profitability and differentiate Omada from competitors.